Rhythmic supplementation of 17beta-estradiol according to the physiological estrous cycle: effect on blood pressure in female ovariectomized rats.
Female Wistar-Kyoto rats (WKY) show a 4-day estrous cycle. The aim of this study was to examine the impact of 17beta-estradiol supplementation every fourth day to ovariectomized rats - mimicking the physiological estrous cycle - on regulation of blood pressure. We monitored blood pressure telemetrically in intact females, ovariectomized (OVX), and ovariectomized WKY injected subcutaneously with 17beta-estradiol (OVX (E2)) in a 4-day rhythm for 24 weeks. Blood pressure decreased both in intact females and OVX (E2), whereas that of OVX persisted at constant levels. The underlying mechanisms studied include the nitric oxide pathway, the rennin-angiotensin system as well as the endothelin system. Serum and urinary nitrate/nitrite (NOx) as well as aortic eNOS decreased in OVX and were restored to normal in OVX (E2). Conversely, caveolin-1 was higher in OVX than in intact females and OVX (E2) while Hsp90 did not differ among groups. Plasma angiotensin II and aortic AT (1) receptor expression increased in OVX and were normalized in OVX (E2). AT (2) receptor expression was regulated reciprocally. Serum endothelin-1 was significantly elevated in OVX and OVX (E2). There was no difference in aortic ET (A) receptor expression between groups whereas ET (B) receptor expression was higher in intact females and OVX (E2) than in OVX. The study suggests that supplementation of 17beta-estradiol in female WKY according to the natural estrous cycle maintains the physiological blood pressure encompassing vasorelaxing and vasoconstricting pathways. The physiological estrous cycle should be kept in mind when cardiovascular data are to be collected/interpreted under estrogen supplementation.
Grundt
A
A
Institute of Experimental and Clinical Pharmacology and Toxicology, Ruprecht-Karls-Universität Heidelberg, Mannheim, Germany.
Grundt
C
C
Knoth
K
K
Lemmer
B
B
D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D019332:Endothelin-1 / Q000378:metabolism; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood / Q000652:urine; D030762:Estrous Cycle / Q000187:drug effects*; D005260:Female; D007279:Injections, Subcutaneous; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010052:Ovariectomy; D051381:Rats; D011921:Rats, Inbred WKY; D044022:Receptor, Endothelin A / Q000378:metabolism; D044023:Receptor, Endothelin B / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects
D019332:Endothelin-1; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D000804:Angiotensin II; D004958:Estradiol; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III